Call (844) 879-2237

Request additional information regarding our products

A Material Development Company

A bioscience company commercializing a portfolio of fully synthetic electrospun scaffolds for medical applications

Feature image

The FDA cleared Acera’s first product in March 2016 and its second product in April 2017, both via 510(k). Acera is currently raising Series A financing, as well as seeking strategic partners for product development and commercialization.

Feature image
Premium WordPress Themes with Single Click

The Theme had a simple layout which attracts the Client to the Website. Also, the professional and Clean design .

Feature image
Acera Meshes
Biologic Properties

The Theme had a simple layout which attracts the Client to the Website. Also, the professional and Clean design .

Feature image
Acera Performance
Investment Opportunities

The Theme had a simple layout which attracts the Client to the Website. Also, the professional and Clean design .

Acera News

Acera Surgical Awarded Federal Supply Schedule (FSS) Contract for Restrata® Wound Matrix

St. Louis, MO, August 8, 2018 – Acera Surgical, a leader in implantable nanomedical scaffolds, announced today that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) contract, effective August […]

Read More

Dr. Matthew Regulski to Present Clinical Results of RestrataⓇ Wound Matrix at  International Wound Care Conference

St. Louis, Missouri, June 12, 2018 – Dr. Matthew Regulski, DPM, will be giving a presentation titled “Clinical Evaluation of a Novel Nanofiber Matrix For the Treatment of Chronic Wounds” at the International Conference on Wound Care, Tissue Repair & […]

Read More